Analyses also showed that Shinbaro 2 administration led to a dose-dependent reduction in disc-degeneration-related factors, such as matrix metalloproteinase (MMP) 9, MMP13, and ADAMTS-5, at the protein and mRNA levels [21]. This evidence concerns the gene MMP13 and intervertebral disk degenerative disorder.